跳至主要内容
临床试验/NCT05302050
NCT05302050Unknown不适用

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus

Better Therapeutics2 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2022年3月7日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
500
试验地点
2
主要终点
Change in HbA1c

研究概览

简要总结

Randomized, controlled, pragmatic trial with open-label extension evaluating BT-001, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control.

详细描述

The study intervention, BT-001 (the App), will be dispensed at enrollment to the Immediate Intervention App Use arm of the trial. Patients randomized to the Delayed Intervention App Use arm will be provided a "control App" with diabetes control, and then the BT-001 App after 180 days. Each participant is assigned to one 90-day treatment cycle of BT-001. Over the 12-month intervention period, study participants will be able to opt into up to 3 additional treatment cycles of BT-001. Study schema is included at the end of this section

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

open label

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Current (within 3 months prior to enrollment) HbA1c >=7.01%
  • Possession of and ability to use Android or iPhone mobile phone
  • Speaks and reads in English
  • Willing to measure frequent fasting finger glucose measurements as part of the App utilization

排除标准

  • Current use of insulin other than a long-acting insulin analogue or human NPH insulin
  • HbA1c >=11%
  • Cognitive impairment or degenerative neuropsychiatric condition (e.g. Alzheimer's, dementia, mixed dementia, other significant memory loss, schizophrenia), or any other condition that in the Investigator's opinion may prevent patient from completing study activities
  • Any terminal medical condition with life expectancy of < 1 year.

结局指标

主要结局

Change in HbA1c

时间窗: Baseline and Day 180

Change in HbA1c from baseline (enrollment) to 6 months after enrollment between groups.

次要结局

  • Change in HbA1c(Baseline and day 180, 365)
  • Significant change in HbA1c(Baseline and Day 365)

研究者

发起方
Better Therapeutics
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验